The phase III PACIFIC trial investigated the use of durvalumab, an anti-PD-L1 antibody, as consolidative therapy following definitive chemoradiation compared to placebo in patients with nonoperable stage III NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.